AR094537A1 - COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa - Google Patents

COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa

Info

Publication number
AR094537A1
AR094537A1 ARP130104090A ARP130104090A AR094537A1 AR 094537 A1 AR094537 A1 AR 094537A1 AR P130104090 A ARP130104090 A AR P130104090A AR P130104090 A ARP130104090 A AR P130104090A AR 094537 A1 AR094537 A1 AR 094537A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
case
heteroatoms selected
carbon atoms
Prior art date
Application number
ARP130104090A
Other languages
English (en)
Inventor
M Moslin Ryan
S Weinstein David
T Wrobleski Stephen
Zhang Yanlei
S Tokarski John
E Mertzman Michael
Liu Chunjian
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to ARP130104090A priority Critical patent/AR094537A1/es
Priority to TW102140574A priority patent/TWI582077B/zh
Priority to HUE14702707A priority patent/HUE046052T2/hu
Priority to EA201690865A priority patent/EA033272B1/ru
Priority to RS20191041A priority patent/RS59125B1/sr
Priority to CN201480072423.2A priority patent/CN106660960B/zh
Priority to ES14702707T priority patent/ES2738826T3/es
Priority to MX2016005853A priority patent/MX369394B/es
Priority to PCT/US2014/011769 priority patent/WO2015069310A1/en
Priority to US15/034,915 priority patent/US9663467B2/en
Priority to SI201431231T priority patent/SI3066078T1/sl
Priority to NZ720710A priority patent/NZ720710A/en
Priority to BR112016010172-3A priority patent/BR112016010172B1/pt
Priority to PE2016000603A priority patent/PE20160961A1/es
Priority to MYPI2016701601A priority patent/MY174453A/en
Priority to KR1020167014612A priority patent/KR102186633B1/ko
Priority to PL14702707T priority patent/PL3066078T3/pl
Priority to JP2016528221A priority patent/JP6312823B2/ja
Priority to DK14702707.2T priority patent/DK3066078T3/da
Priority to EP19173861.6A priority patent/EP3590926A1/en
Priority to CA2930060A priority patent/CA2930060C/en
Priority to LTEP14702707.2T priority patent/LT3066078T/lt
Priority to PT14702707T priority patent/PT3066078T/pt
Priority to MA39001A priority patent/MA39001A1/fr
Priority to AU2014347275A priority patent/AU2014347275B2/en
Priority to EP14702707.2A priority patent/EP3066078B1/en
Priority to TN2016000153A priority patent/TN2016000153A1/en
Publication of AR094537A1 publication Critical patent/AR094537A1/es
Priority to PH12016500779A priority patent/PH12016500779A1/en
Priority to IL245448A priority patent/IL245448B/en
Priority to CL2016001101A priority patent/CL2016001101A1/es
Priority to HK16114678A priority patent/HK1226400A1/zh
Priority to US15/480,787 priority patent/US9987266B2/en
Priority to HRP20191368 priority patent/HRP20191368T1/hr
Priority to CY20191100878T priority patent/CY1122065T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides

Abstract

Son útiles para la modulación de IL-12, IL-23 y/o lFNa que actúan en Tyk-2 para generar la inhibición de la transducción de señal. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), o un estereoisómero o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde R¹ es alquilo C₁₋₃ opcionalmente sustituido con 0 - 7 R¹ᵃ; R¹ᵃ es, en cada caso, independientemente hidrógeno, deuterio, F, CI, Br, CF₃ o CN; R² es alquilo C₁₋₆ sustituido con 0 - 4 R²ᵃ, cicloalquilo C₃₋₆ sustituido con 0 - 4 R²ᵃ, arilo C₆₋₁₀ sustituido con 0 - 4 R²ᵃ, un heterociclo de 5 - 14 miembros que contiene 1 - 4 heteroátomos seleccionados de N, O y S, sustituido con 0 - 4 R²ᵃ, NR⁶R⁶ u ORᵇ; R²ᵃ es, en cada caso, independientemente hidrógeno, =O, halo, OCF₃, CN, NO₂, -(CH₂)ʳORᵇ, -(CH₂)ʳSRᵇ, -(CH₂)ʳC(O)Rᵇ, -(CH₂)ʳC(O)ORᵇ, -(CH₂)ʳOC(O)Rᵇ, -(CH₂)ʳNR¹¹R¹¹, -(CH₂)ʳC(O)NR¹¹R¹¹, -(CH₂)ʳNRᵇC(O)Rᶜ, -(CH₂)ʳNRᵇC(O)ORᶜ, -NRᵇC(O)NR¹¹R¹¹, -S(O)ₚNR¹¹R¹¹, -NRᵇS(O)ₚRᶜ, -S(O)ₚRᶜ, alquilo C₁₋₆ sustituido con 0 - 3 Rᵃ, haloalquilo C₁₋₆, -(CH₂)ʳ-carbociclo de 3 - 14 miembros sustituido con 0 - 1 Rᵃ o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono o 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 2 Rᵃ; o un R²ᵃ y otro R²ᵃ, junto con los átomos a los que están unidos, se combinan para formar un anillo fusionado de 5 - 6 miembros, en donde el anillo fusionado se puede sustituir con 0 - 2 Rᵃ; R³ es -(CH₂)ʳ-carbociclo de 3 - 14 miembros sustituido 0 - 5 R³ᵃ; R³ᵃ es, en cada caso, independientemente hidrógeno, =O, halo (F), OCF₃, CF₃, CHF₂, CN, NO₂, -(CH₂)ʳORᵇ, -(CH₂)ʳSRᵇ, -(CH₂)ʳC(O)Rᵇ, -(CH₂)ʳC(O)ORᵇ, -(CH₂)ʳOC(O)Rᵇ, -(CH₂)ʳNR¹¹R¹¹, -(CH₂)ʳC(O)NR¹¹R¹¹, -(CH₂)ʳNRᵇC(O)Rᶜ, -(CH₂)ʳNRᵇC(O)ORᶜ, -NRᵇC(O)NR¹¹R¹¹, -S(O)ₚNR¹¹R¹¹, -NRᵇS(O)ₚRᶜ, -S(O)ₚRᶜ, alquilo C₁₋₆ sustituido con 0 - 3 Rᵃ, haloalquilo C₁₋₆, -(CH₂)ʳ-carbociclo de 3 - 14 miembros sustituido con 0 - 3 Rᵃ o -(CH₂)ʳ-heterociclo de 5 - 10 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 3 Rᵃ; o dos R³ᵃ, junto con los átomos a los que están unidos, se combinan para formar un anillo fusionado, en donde el anillo se selecciona de fenilo y un heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, S u O, y ese anillo fenilo fusionado también se puede sustituir con Rᵃ; R⁴ y R⁵ son independientemente hidrógeno, alquilo C₁₋₄ sustituido con 0 - 1 Rᶠ, (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᵈ o -(CH₂)-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ; R⁶ y R¹¹ son, en cada caso, independientemente hidrógeno, alquilo C₁₋₄ sustituido con 0 - 3 Rᶠ, CF₃, cicloalquilo C₃₋₁₀ sustituido con 0 - 1 Rᶠ, (CH)ʳ-fenilo sustituido con 0 - 3 Rᵈ o (CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 3 Rᵈ; Rᵃ es, en cada caso, hidrógeno, F, CI, Br, OCF₃, CF₃, CHF₂, CN, NO₂, -(CH₂)ʳORᵇ, -(CH₂)ʳSRᵇ, -(CH₂)ʳC(O)Rᵇ, -(CH₂)ʳC(O)ORᵇ, -(CH₂)ʳOC(O)Rᵇ, -(CH₂)ʳNR¹¹R¹¹, -(CH₂)ʳC(O)NR¹¹R¹¹, -(CH₂)ʳNRᵇC(O)Rᶜ, -(CH₂)ʳNRᵇC(O)ORᶜ, -NRᵇC(O)NR¹¹R¹¹, -S(O)ₚNR¹¹R¹¹, -NRᵇS(O)Rᶜ, -S(O)Rᶜ, -S(O)₂Rᶜ, alquilo C₁₋₆ sustituido con 0 - 3 Rᶠ, haloalquilo C₁₋₆, -(CH₂)ʳ-carbociclo de 3 - 14 miembros o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 3 Rᶠ; Rᵇ es, en cada caso, hidrógeno, alquilo C₁₋₆ sustituido con 0 - 3 Rᵈ, haloalquilo C₁₋₆, cicloalquilo C₃₋₆ sustituido con 0 - 2 Rᵈ, o -(CH₂)ʳ-heterociclo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ sustituido con 0 - 3 Rᶠ o (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᵈ; Rᶜ es alquilo C₁₋₆ sustituido con 0 - 3 Rᶠ, (CH₂)ʳ-cicloalquilo C₃₋₆ sustituido con 0 - 3 Rᶠ o (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᶠ; Rᵈ es, en cada caso, independientemente hidrógeno, F, CI, Br, OCF₃, CF₃, CN, NO₂, -ORᵉ, -(CH₂)ʳ-C(O)Rᶜ, -NRᵉRᵉ, -NRᵉC(O)ORᶜ, alquilo C₁₋₆ o (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᶠ; Rᵉ se selecciona, independientemente en cada caso, de hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ y (CH₂)ʳ-fenilo sustituido con 0 - 3 Rᶠ; Rᶠ es, en cada caso, independientemente hidrógeno, halo, CN, NH₂, OH, cicloalquilo C₃₋₆, CF₃, O(alquilo C₁₋₆) o -(CH₂)ʳ-heteroarilo de 5 - 7 miembros que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, O y S(O)ₚ; p es 0, 1 ó 2; y r es 0, 1, 2, 3 ó 4.
ARP130104090A 2013-11-07 2013-11-07 COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa AR094537A1 (es)

Priority Applications (34)

Application Number Priority Date Filing Date Title
ARP130104090A AR094537A1 (es) 2013-11-07 2013-11-07 COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
TW102140574A TWI582077B (zh) 2013-11-07 2013-11-07 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
JP2016528221A JP6312823B2 (ja) 2013-11-07 2014-01-16 Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節因子として有用なアルキル−アミド−置換ピリジル化合物
EP19173861.6A EP3590926A1 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
RS20191041A RS59125B1 (sr) 2013-11-07 2014-01-16 Alkil-amid-supstituisana piridil jedinjenja korisna kao modulatori il-12, il-23 i/ili ifnalfa odgovora
DK14702707.2T DK3066078T3 (da) 2013-11-07 2014-01-16 Alkyl-amid-substituerede pyridylforbindelser, der er anvendelige som modulatorer af il-12-, il-23- og/eller ifn-alpha-responser
ES14702707T ES2738826T3 (es) 2013-11-07 2014-01-16 Compuestos de piridilo sustituidos con alquilamida útiles como moduladores de respuestas de IL-12, IL-23 y/o IFNalfa
MX2016005853A MX369394B (es) 2013-11-07 2014-01-16 Compuestos de piridilo sustituidos con alquilamida utiles como muduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa).
PCT/US2014/011769 WO2015069310A1 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
EA201690865A EA033272B1 (ru) 2013-11-07 2014-01-16 АЛКИЛАМИД-ЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ОТВЕТОВ IL-12, IL-23 И/ИЛИ IFNα
SI201431231T SI3066078T1 (sl) 2013-11-07 2014-01-16 Alkil-amid-substituirane spojine piridila uporabne kot modulatorji IL-12, IL-23 in/ali IFN-ALFA odgovorov
NZ720710A NZ720710A (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
BR112016010172-3A BR112016010172B1 (pt) 2013-11-07 2014-01-16 Compostos de piridila substituída por alquil- amida úteis no tratamento de uma doença inflamatória ou autoimune e composição farmacêutica que os compreende
PE2016000603A PE20160961A1 (es) 2013-11-07 2014-01-16 Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa)
MYPI2016701601A MY174453A (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
CA2930060A CA2930060C (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
PL14702707T PL3066078T3 (pl) 2013-11-07 2014-01-16 Związki pirydylowe podstawione alkilo-amidami przydatne jako modulatory odpowiedzi il-12, il-23 i/lub ifn-alfa
HUE14702707A HUE046052T2 (hu) 2013-11-07 2014-01-16 Alkil-amid szubsztituált piridil vegyületek, amelyek hasznosak IL-12, IL-23 és/vagy IFN-alfa reakciók modulátoraiként
CN201480072423.2A CN106660960B (zh) 2013-11-07 2014-01-16 用作IL-12、IL-23和/或IFNα响应的调节剂的烷基-酰胺-取代的吡啶化合物
US15/034,915 US9663467B2 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
KR1020167014612A KR102186633B1 (ko) 2013-11-07 2014-01-16 Il-12, il-23 및/또는 ifn알파 반응의 조정제로서 유용한 알킬-아미드-치환된 피리딜 화합물
LTEP14702707.2T LT3066078T (lt) 2013-11-07 2014-01-16 Alkilamidu-pakeisti piridilo junginiai, naudingi kaip il-12, il-23 ir (arba) ifn-alfa atsako moduliatoriai
PT14702707T PT3066078T (pt) 2013-11-07 2014-01-16 Compostos de piridilo substitoidos com alqoil-amida uteis como modoladores de respostas de il-12, il-23 e/00 ifn-alfa
MA39001A MA39001A1 (fr) 2013-11-07 2014-01-16 Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn?
AU2014347275A AU2014347275B2 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
EP14702707.2A EP3066078B1 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
TN2016000153A TN2016000153A1 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses.
PH12016500779A PH12016500779A1 (en) 2013-11-07 2016-04-27 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
IL245448A IL245448B (en) 2013-11-07 2016-05-03 Alkyl-amide substituted pyridyl compounds useful as modulators of responses to il-12, il-23, and/or ifnalpha
CL2016001101A CL2016001101A1 (es) 2013-11-07 2016-05-06 Compuestos de piridilo sustituidos con alquilamida útiles como moduladores de respuestas de il-12 e il-23 y/o ifnalfa
HK16114678A HK1226400A1 (zh) 2013-11-07 2016-12-23 作為il-12，il-23調節劑的烷基醯胺取代的吡啶基化合物
US15/480,787 US9987266B2 (en) 2013-11-07 2017-04-06 Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
HRP20191368 HRP20191368T1 (hr) 2013-11-07 2019-07-30 Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora
CY20191100878T CY1122065T1 (el) 2013-11-07 2019-08-14 Ενωσεις αλκυλ-αμιδο-υποκατεστημενου πυριδυλιου χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ιfναλφα

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ARP130104090A AR094537A1 (es) 2013-11-07 2013-11-07 COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
TW102140574A TWI582077B (zh) 2013-11-07 2013-11-07 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
VE140013 2013-11-11
PCT/US2014/011769 WO2015069310A1 (en) 2013-11-07 2014-01-16 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Publications (1)

Publication Number Publication Date
AR094537A1 true AR094537A1 (es) 2015-08-12

Family

ID=56241743

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104090A AR094537A1 (es) 2013-11-07 2013-11-07 COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa

Country Status (31)

Country Link
US (2) US9663467B2 (es)
EP (2) EP3590926A1 (es)
JP (1) JP6312823B2 (es)
KR (1) KR102186633B1 (es)
CN (1) CN106660960B (es)
AR (1) AR094537A1 (es)
AU (1) AU2014347275B2 (es)
CA (1) CA2930060C (es)
CL (1) CL2016001101A1 (es)
CY (1) CY1122065T1 (es)
DK (1) DK3066078T3 (es)
EA (1) EA033272B1 (es)
ES (1) ES2738826T3 (es)
HK (1) HK1226400A1 (es)
HR (1) HRP20191368T1 (es)
HU (1) HUE046052T2 (es)
IL (1) IL245448B (es)
LT (1) LT3066078T (es)
MA (1) MA39001A1 (es)
MX (1) MX369394B (es)
MY (1) MY174453A (es)
NZ (1) NZ720710A (es)
PE (1) PE20160961A1 (es)
PH (1) PH12016500779A1 (es)
PL (1) PL3066078T3 (es)
PT (1) PT3066078T (es)
RS (1) RS59125B1 (es)
SI (1) SI3066078T1 (es)
TN (1) TN2016000153A1 (es)
TW (1) TWI582077B (es)
WO (1) WO2015069310A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2890935A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
EP4071144A1 (en) 2012-11-08 2022-10-12 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP3016932B1 (en) 2013-07-01 2019-02-27 Bristol-Myers Squibb Company Ido inhibitors
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
TW201713663A (zh) 2015-06-24 2017-04-16 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
UY36748A (es) 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
EP3526222B1 (en) * 2016-10-14 2022-08-17 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN110114357B (zh) 2016-10-28 2022-05-31 百时美施贵宝公司 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物
JP7012082B2 (ja) * 2016-11-17 2022-01-27 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤
US10294256B2 (en) * 2016-12-13 2019-05-21 Bristol-Myers Squibb Company Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses
BR112019020163A2 (pt) 2017-03-30 2020-04-22 Bristol-Myers Squibb Company forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metóxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3) piridazina-3-carboxamida
EP3621960B1 (en) 2017-05-11 2021-08-04 Bristol-Myers Squibb Company Thienopyridines and benzothiophenes useful as irak4 inhibitors
AU2018371010B2 (en) * 2017-11-21 2022-06-09 Bristol-Myers Squibb Company Sulfone pyridine alkyl amide-substituted heteroaryl compounds
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
JP2021534180A (ja) * 2018-08-16 2021-12-09 イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. 置換４−アミノ−１Ｈ−イミダゾ［４，５−ｃ］キノリン化合物およびその製造の改良法
EP3870579A4 (en) * 2018-10-22 2022-10-19 Alumis Inc. TYK2 INHIBITORS AND THEIR USES
US20230020273A1 (en) * 2018-10-30 2023-01-19 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
JP2022524279A (ja) * 2019-01-28 2022-05-02 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ピリダジン系誘導体阻害剤、その製造方法及び使用
BR112021014709A2 (pt) * 2019-01-30 2021-09-28 Bristol-Myers Squibb Company Compostos piridina ou piridazina dissubstituídos por amida
IL287665A (en) 2019-04-30 2022-07-01 Celgene Corp Combined treatments including apremilaste and tyk2 inhibitors
US20220204495A1 (en) * 2019-05-03 2022-06-30 Valo Health, Inc. Inhibiting trabid
WO2021011513A1 (en) 2019-07-16 2021-01-21 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
CA3170773A1 (en) * 2020-03-11 2021-09-16 Xiangyang Chen Heterocyclic compounds for inhibiting tyk2 activities
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
EP4136073A1 (en) * 2020-04-14 2023-02-22 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
CN113563309A (zh) * 2020-04-28 2021-10-29 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
US20230167092A1 (en) * 2020-04-28 2023-06-01 Bristol-Myers Squibb Company Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
EP4308556A1 (en) * 2021-03-16 2024-01-24 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP2024517453A (ja) * 2021-05-04 2024-04-22 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
CA3232812A1 (en) 2021-09-23 2023-03-30 Ian MacQuarie CATLETT Methods of treating hair-loss disorders with tyk2 inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023109954A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
WO2023213308A1 (zh) * 2022-05-05 2023-11-09 苏州隆博泰药业有限公司 酰胺取代的杂环化合物及其医药用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024042363A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2024042361A1 (en) * 2022-08-24 2024-02-29 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
AR077033A1 (es) * 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
EP2794569B1 (en) * 2011-12-21 2017-05-10 Biota Europe Ltd Heterocyclic urea compounds
AU2012357038B2 (en) * 2011-12-23 2016-05-12 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
CA2890929A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
CA2890935A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
EP4071144A1 (en) 2012-11-08 2022-10-12 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Also Published As

Publication number Publication date
LT3066078T (lt) 2019-07-25
AU2014347275B2 (en) 2017-12-07
KR20160071475A (ko) 2016-06-21
WO2015069310A1 (en) 2015-05-14
ES2738826T3 (es) 2020-01-27
TW201420572A (zh) 2014-06-01
IL245448A0 (en) 2016-06-30
CN106660960B (zh) 2019-11-08
EP3066078A1 (en) 2016-09-14
US9987266B2 (en) 2018-06-05
CA2930060C (en) 2020-03-24
PT3066078T (pt) 2019-08-01
DK3066078T3 (da) 2019-08-26
EP3066078B1 (en) 2019-05-22
PL3066078T3 (pl) 2019-10-31
AU2014347275A1 (en) 2016-06-23
PE20160961A1 (es) 2016-10-08
CA2930060A1 (en) 2015-05-14
HK1226400A1 (zh) 2017-09-29
MY174453A (en) 2020-04-20
MX369394B (es) 2019-11-07
US20170209426A1 (en) 2017-07-27
US9663467B2 (en) 2017-05-30
SI3066078T1 (sl) 2019-08-30
BR112016010172A2 (pt) 2017-08-08
PH12016500779A1 (en) 2016-05-30
MA39001A1 (fr) 2017-10-31
CL2016001101A1 (es) 2016-12-16
CY1122065T1 (el) 2020-11-25
JP2017512749A (ja) 2017-05-25
HRP20191368T1 (hr) 2019-11-29
EA201690865A1 (ru) 2017-01-30
IL245448B (en) 2019-08-29
CN106660960A (zh) 2017-05-10
EP3590926A1 (en) 2020-01-08
TN2016000153A1 (en) 2017-10-06
EA033272B1 (ru) 2019-09-30
RS59125B1 (sr) 2019-09-30
US20160280649A1 (en) 2016-09-29
NZ720710A (en) 2019-12-20
JP6312823B2 (ja) 2018-04-18
MX2016005853A (es) 2016-07-13
KR102186633B1 (ko) 2020-12-03
HUE046052T2 (hu) 2020-02-28
TWI582077B (zh) 2017-05-11

Similar Documents

Publication Publication Date Title
AR094537A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AR094452A1 (es) COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa
AR093403A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR113895A1 (es) Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR090868A1 (es) Composiciones plaguicidas y procesos relacionados con ellas
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR108906A1 (es) Heterociclos de biarilmetilo
AR100328A1 (es) Moduladores pirrolidina de gpr40
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR095422A1 (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
AR106604A1 (es) Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico
AR092749A1 (es) Compuestos farmaceuticos

Legal Events

Date Code Title Description
FG Grant, registration